## Diane Havlir

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11978436/publications.pdf

Version: 2024-02-01

24 papers

11,720 citations

331538
21
h-index

610775 24 g-index

24 all docs

24 docs citations

times ranked

24

10724 citing authors

#	Article	IF	CITATIONS
1	What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?. Journal of the International AIDS Society, 2020, 23, e25455.	1.2	96
2	Financial incentives for achieving and maintaining viral suppression among HIV-positive adults in Uganda: a randomised controlled trial. Lancet HIV,the, 2019, 6, e155-e163.	2.1	32
3	RAPID antiretroviral therapy. Aids, 2019, 33, 825-832.	1.0	83
4	Comparative assessment of five trials of universal <scp>HIV</scp> testing and treatment in subâ€Saharan Africa. Journal of the International AIDS Society, 2018, 21, e25048.	1,2	81
5	Trends in the San Francisco Human Immunodeficiency Virus Epidemic in the "Getting to Zero―Era. Clinical Infectious Diseases, 2018, 66, 1027-1034.	2.9	41
6	Degree of Housing Instability Shows Independent "Dose-Response―With Virologic Suppression Rates Among People Living With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 2018, 5, ofy035.	0.4	41
7	High CD4 counts associated with better economic outcomes for HIV-positive adults and their HIV-negative household members in the SEARCH Trial. PLoS ONE, 2018, 13, e0198912.	1.1	7
8	Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Societyâ€"Lancet Commission. Lancet, The, 2018, 392, 312-358.	6.3	230
9	Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa. JAMA - Journal of the American Medical Association, 2017, 317, 2196.	3.8	116
10	High rates of viral suppression in adults and children with high CD4+ counts using a streamlined ART delivery model in the SEARCH trial in rural Uganda and Kenya. Journal of the International AIDS Society, 2017, 20, 21673.	1.2	57
11	Expectations about future health and longevity in Kenyan and Ugandan communities receiving a universal test-and-treat intervention in the SEARCH trial. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 90-98.	0.6	8
12	Antiretroviral Therapy for the Prevention of HIV-1 Transmission. New England Journal of Medicine, 2016, 375, 830-839.	13.9	1,282
13	Implementation challenges for long-acting antivirals as treatment. Current Opinion in HIV and AIDS, 2015, 10, 282-289.	1.5	33
14	Virologic and Immunologic Outcomes of HIV-Infected Ugandan Children Randomized to Lopinavir/Ritonavir or Nonnucleoside Reverse Transcriptase Inhibitor Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 535-541.	0.9	22
15	Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infectious Diseases, The, 2014, 14, 281-290.	4.6	423
16	Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. Aids, 2013, 27, 1159-1165.	1.0	23
17	Prevention of HIV-1 Infection with Early Antiretroviral Therapy. New England Journal of Medicine, 2011, 365, 493-505.	13.9	6,046
18	Class-Sparing Regimens for Initial Treatment of HIV-1 Infection. New England Journal of Medicine, 2008, 358, 2095-2106.	13.9	667

#	Article	IF	CITATION
19	Dynamics of Total, Linear Nonintegrated, and Integrated HIV†DNA In Vivo and In Vitro. Journal of Infectious Diseases, 2008, 197, 411-419.	1.9	149
20	Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. Aids, 2003, 17, 2345-2349.	1.0	52
21	Coadministration of Indinavir and Nelfinavir in Human Immunodeficiency Virus Type 1-Infected Adults: Safety, Pharmacokinetics, and Antiretroviral Activity. Antimicrobial Agents and Chemotherapy, 2002, 46, 3877-3882.	1.4	7
22	3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine. Annals of Internal Medicine, 2000, 133, 35.	2.0	173
23	Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 Infection. JAMA - Journal of the American Medical Association, 1998, 280, 35.	3.8	228
24	Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy. New England Journal of Medicine, 1997, 337, 734-739.	13.9	1,823